Error message

There was an error processing your request.

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

Vivos Inc (PK:RDGL)

Business Focus: Medical Imaging Systems

Sector:  Healthcare Industry:  Advanced Medical Equipment & Technology
 
See Regulatory Filings on SEC
Company Contact
Address: 719 Jadwin Ave
RICHLAND WA 99352-4217
Tel: N/A
Website: https://www.radiogel.com
IR: See website
Key People
Carlton M. Cadwell
Chairman of the Board, Secretary
Michael K. Korenko
President, Chief Executive Officer, Director
Michael Pollack
Interim Chief Financial Officer
Business Overview
Vivos Inc. is a radiation oncology medical device company. The Company is engaged in the development of its yttrium-90 (Y-90) based brachytherapy device, RadioGel, for the treatment of non-resectable tumors. RadioGel is a device for human therapy for non-resectable cancers in humans. It is a hydrogel liquid containing tiny Yttrium-90 phosphate microparticles that may be administered directly into a tumor. The Company's IsoPet division is focused on bringing RadioGel yttrium-90 precision radionuclide therapy to veterinary oncologists to treat dogs, cats and horses suffering from cancerous tumors. The IsoPet solutions division used university veterinary hospitals to demonstrate the safety and therapeutic effectiveness for different animal cancers. The Company is also engaged in developing a micro-injection system for small tumor therapy for treating cancerous thyroid lymph nodes.
Financial Overview
For the three months ended 31 March 2024, Vivos Inc revenues decreased 25% to $5K. Net loss increased from $248K to $559K. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Higher net loss reflects Professional fees increase from $84K to $404K (expense), Payroll expenses increase of 26% to $91K (expense), Research and development increase of 24% to $57K (expense).